- Published on
Emergency And Acute Medicine – Hepatic Encephalopathy
Basics And Description
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome characterized by alterations in behavior, level of consciousness, and motor function resulting from hepatic insufficiency and the accumulation of substances normally detoxified by the liver. The condition arises from a multifactorial process, most notably the accumulation of ammonia produced from protein degradation by colonic bacteria and deamination of glutamine in the small bowel, kidneys, and muscle. Ammonia crosses the blood–brain barrier and is metabolized by astrocytes into glutamine, leading to astrocytic swelling, cerebral edema, and mitochondrial dysfunction. Additional neurotoxins such as short-chain fatty acids, manganese, neurosteroids, phenols, mercaptans, and amino acids including tryptophan also contribute. Neurotransmitter imbalance plays a role, with increased inhibitory neurotransmitters such as benzodiazepines, γ-aminobutyric acid, and serotonin, and decreased excitatory neurotransmitters including glutamate, dopamine, aspartate, and catecholamines. Other contributing factors include reduced cerebral blood flow and oxygen delivery, increased cerebral glucose utilization with potential hypoglycemia, zinc deficiency affecting urea cycle enzymes, and rare inherited urea cycle disorders.
Etiology
Hepatic encephalopathy is classified according to the 11th World Congress of Gastroenterology. Type A is associated with acute liver injury and fulminant hepatic failure. Type B is related to portosystemic shunting without intrinsic liver disease. Type C is associated with cirrhosis and portal hypertension. Common precipitating factors include gastrointestinal bleeding, electrolyte abnormalities such as hypokalemia and hyponatremia, metabolic alkalosis reducing renal ammonium excretion, sepsis including spontaneous bacterial peritonitis, constipation, noncompliance with treatment in chronic liver disease, high-protein diet, hypoglycemia, hypovolemia following large-volume paracentesis, azotemia from diuretics or diarrhea, sedatives or narcotics including alcohol, zinc deficiency, hepatocellular injury from viral or drug-induced hepatitis, and post portosystemic shunt placement. Recurrent episodes may occur even without identifiable triggers.
Diagnosis – Signs And Symptoms
Type A HE progresses rapidly and may lead to seizures, decerebrate rigidity, coma, and death from cerebral edema. Type B and C HE are typically chronic and may present as minimal or overt encephalopathy. Minimal HE manifests as impaired psychomotor speed, attention, concentration, visual perception, memory deficits, and slowed mental processing, detectable only with psychometric testing. Overt HE includes slow and monotonous speech, impaired fine motor skills, hyperreflexia, clonus, hyperventilation, extrapyramidal movements, seizures, confusion, coma, and abnormal posturing. Episodic HE is characterized by transient changes in consciousness over hours to days with return to baseline after treatment, whereas persistent HE does not fully resolve.
Clinical Grading (West Haven Criteria)
Stage 0 shows no overt clinical changes but abnormal neuropsychological testing and no asterixis. Stage I includes personality changes, irritability, depression or euphoria, sleep–wake reversal, impaired writing or calculations, and possible asterixis. Stage II is marked by inappropriate behavior, lethargy, slowed responses, asterixis, slurred speech, and ataxia. Stage III presents with disorientation, amnesia, paranoia, nystagmus, hypoactive reflexes, positive Babinski sign, and stupor. Stage IV is characterized by coma and dilated pupils.
Essential Workup
Evaluation should include a detailed history of liver disease and prior HE episodes, identification of precipitating factors, and assessment for electrolyte disturbances, as even mild abnormalities may cause significant clinical deterioration.
Diagnostic Tests And Interpretation
Ammonia levels correlate poorly with disease severity but may assist in evaluating unexplained altered mental status. Samples must be handled correctly and processed promptly. A normal ammonia level should prompt investigation for alternative diagnoses. Additional studies include fecal occult blood testing and nasogastric lavage to assess for gastrointestinal bleeding, complete blood count for anemia or infection, electrolytes, renal function, glucose, coagulation studies, and liver enzymes. Urinalysis and cultures of urine and ascitic fluid help identify infection. Toxicology screening may be required to exclude other causes of altered consciousness. Additional testing may include thyroid function, arterial blood gases, magnesium, and viral serologies. Imaging includes chest radiography for pneumonia or heart failure and head CT for new-onset altered mental status, focal deficits, trauma, or suspected cerebral edema. Brain MRI may aid diagnosis in patients with portosystemic shunts without intrinsic liver disease. ECG assesses arrhythmias and electrolyte effects. Lumbar puncture is indicated for unexplained or worsening symptoms, and paracentesis is required when spontaneous bacterial peritonitis is suspected. EEG typically shows generalized slowing.
Differential Diagnosis
Consider alcohol withdrawal, cerebrovascular accident, congestive heart failure, carbon dioxide narcosis, head trauma, electrolyte disturbances, hypoglycemia, meningitis, encephalitis, metabolic encephalopathies, psychiatric illness, drug or alcohol intoxication, uremia, and in children, Reye syndrome or fatty acid oxidation disorders.
Initial Stabilization And Therapy
Management includes supplemental oxygen, cardiac monitoring, and airway protection, with intubation required for grade III or IV encephalopathy. Propofol is preferred for sedation if needed. Standard initial altered mental status treatment includes naloxone, glucose administration, and thiamine.
Emergency Department Treatment And Procedures
Identification and correction of precipitating factors is central to management. Frequent glucose monitoring is essential due to the risk of hypoglycemia. Complications such as gastrointestinal bleeding, sepsis, electrolyte abnormalities, coagulopathy, and renal dysfunction must be treated promptly. Sedatives and narcotics should be avoided when possible; if required, agents with minimal hepatic metabolism are preferred. Ammonia reduction is achieved with nonabsorbable disaccharides such as lactulose, administered orally, via nasogastric tube, or as retention enemas in severe cases. Intestinal flora reduction may include rifaximin, neomycin, metronidazole, or vancomycin, often in combination with lactulose. Rifaximin is preferred for lactulose-resistant HE due to its efficacy and favorable safety profile. Cerebral edema should be treated promptly if present. Zinc deficiency should be corrected, and short-term protein restriction may be considered. Flumazenil may provide transient improvement in select patients but should be avoided in chronic benzodiazepine or alcohol users. Liver transplantation is the definitive therapy for severe or recurrent HE. Additional therapies under investigation include L-carnitine, albumin dialysis, N-acetylcysteine, probiotics, branched-chain amino acids, and manganese chelation.
Medications
Therapy may include intravenous dextrose for hypoglycemia, lactulose titrated to achieve two to three soft stools daily, rifaximin 550 mg twice daily, neomycin or metronidazole when indicated, naloxone for suspected opioid effect, thiamine supplementation, zinc acetate or sulfate, and mannitol for cerebral edema.
Follow-Up And Disposition
Patients with grade II to IV HE, type A HE of any grade, type B or C HE grade II or higher, associated complications such as sepsis or gastrointestinal bleeding, or diagnostic uncertainty require admission, often to the intensive care unit with gastroenterology consultation. Discharge may be considered for patients with known chronic HE presenting with grade 0 or I symptoms, a reversible cause, and reliable supervision. Discharged patients should receive lactulose therapy and dietary guidance.
Follow-Up Recommendations
Patients should realize the importance of dietary counseling, medication adherence, and alcohol cessation when appropriate. Referral to gastroenterology is recommended for recurrent episodes, and patients with type A HE should be evaluated for liver transplantation.
Clinical Insights And Common Errors
Rifaximin is effective for lactulose-resistant hepatic encephalopathy. Hypoglycemia is common and easily overlooked. Sedatives and narcotics can worsen encephalopathy and should be avoided whenever possible or replaced with agents not metabolized by the liver.
Basics And Description
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome characterized by alterations in behavior, level of consciousness, and motor function resulting from hepatic insufficiency and the accumulation of substances normally detoxified by the liver. The condition arises from a multifactorial process, most notably the accumulation of ammonia produced from protein degradation by colonic bacteria and deamination of glutamine in the small bowel, kidneys, and muscle. Ammonia crosses the blood–brain barrier and is metabolized by astrocytes into glutamine, leading to astrocytic swelling, cerebral edema, and mitochondrial dysfunction. Additional neurotoxins such as short-chain fatty acids, manganese, neurosteroids, phenols, mercaptans, and amino acids including tryptophan also contribute. Neurotransmitter imbalance plays a role, with increased inhibitory neurotransmitters such as benzodiazepines, γ-aminobutyric acid, and serotonin, and decreased excitatory neurotransmitters including glutamate, dopamine, aspartate, and catecholamines. Other contributing factors include reduced cerebral blood flow and oxygen delivery, increased cerebral glucose utilization with potential hypoglycemia, zinc deficiency affecting urea cycle enzymes, and rare inherited urea cycle disorders.
Etiology
Hepatic encephalopathy is classified according to the 11th World Congress of Gastroenterology. Type A is associated with acute liver injury and fulminant hepatic failure. Type B is related to portosystemic shunting without intrinsic liver disease. Type C is associated with cirrhosis and portal hypertension. Common precipitating factors include gastrointestinal bleeding, electrolyte abnormalities such as hypokalemia and hyponatremia, metabolic alkalosis reducing renal ammonium excretion, sepsis including spontaneous bacterial peritonitis, constipation, noncompliance with treatment in chronic liver disease, high-protein diet, hypoglycemia, hypovolemia following large-volume paracentesis, azotemia from diuretics or diarrhea, sedatives or narcotics including alcohol, zinc deficiency, hepatocellular injury from viral or drug-induced hepatitis, and post portosystemic shunt placement. Recurrent episodes may occur even without identifiable triggers.
Diagnosis – Signs And Symptoms
Type A HE progresses rapidly and may lead to seizures, decerebrate rigidity, coma, and death from cerebral edema. Type B and C HE are typically chronic and may present as minimal or overt encephalopathy. Minimal HE manifests as impaired psychomotor speed, attention, concentration, visual perception, memory deficits, and slowed mental processing, detectable only with psychometric testing. Overt HE includes slow and monotonous speech, impaired fine motor skills, hyperreflexia, clonus, hyperventilation, extrapyramidal movements, seizures, confusion, coma, and abnormal posturing. Episodic HE is characterized by transient changes in consciousness over hours to days with return to baseline after treatment, whereas persistent HE does not fully resolve.
Clinical Grading (West Haven Criteria)
Stage 0 shows no overt clinical changes but abnormal neuropsychological testing and no asterixis. Stage I includes personality changes, irritability, depression or euphoria, sleep–wake reversal, impaired writing or calculations, and possible asterixis. Stage II is marked by inappropriate behavior, lethargy, slowed responses, asterixis, slurred speech, and ataxia. Stage III presents with disorientation, amnesia, paranoia, nystagmus, hypoactive reflexes, positive Babinski sign, and stupor. Stage IV is characterized by coma and dilated pupils.
Essential Workup
Evaluation should include a detailed history of liver disease and prior HE episodes, identification of precipitating factors, and assessment for electrolyte disturbances, as even mild abnormalities may cause significant clinical deterioration.
Diagnostic Tests And Interpretation
Ammonia levels correlate poorly with disease severity but may assist in evaluating unexplained altered mental status. Samples must be handled correctly and processed promptly. A normal ammonia level should prompt investigation for alternative diagnoses. Additional studies include fecal occult blood testing and nasogastric lavage to assess for gastrointestinal bleeding, complete blood count for anemia or infection, electrolytes, renal function, glucose, coagulation studies, and liver enzymes. Urinalysis and cultures of urine and ascitic fluid help identify infection. Toxicology screening may be required to exclude other causes of altered consciousness. Additional testing may include thyroid function, arterial blood gases, magnesium, and viral serologies. Imaging includes chest radiography for pneumonia or heart failure and head CT for new-onset altered mental status, focal deficits, trauma, or suspected cerebral edema. Brain MRI may aid diagnosis in patients with portosystemic shunts without intrinsic liver disease. ECG assesses arrhythmias and electrolyte effects. Lumbar puncture is indicated for unexplained or worsening symptoms, and paracentesis is required when spontaneous bacterial peritonitis is suspected. EEG typically shows generalized slowing.
Differential Diagnosis
Consider alcohol withdrawal, cerebrovascular accident, congestive heart failure, carbon dioxide narcosis, head trauma, electrolyte disturbances, hypoglycemia, meningitis, encephalitis, metabolic encephalopathies, psychiatric illness, drug or alcohol intoxication, uremia, and in children, Reye syndrome or fatty acid oxidation disorders.
Initial Stabilization And Therapy
Management includes supplemental oxygen, cardiac monitoring, and airway protection, with intubation required for grade III or IV encephalopathy. Propofol is preferred for sedation if needed. Standard initial altered mental status treatment includes naloxone, glucose administration, and thiamine.
Emergency Department Treatment And Procedures
Identification and correction of precipitating factors is central to management. Frequent glucose monitoring is essential due to the risk of hypoglycemia. Complications such as gastrointestinal bleeding, sepsis, electrolyte abnormalities, coagulopathy, and renal dysfunction must be treated promptly. Sedatives and narcotics should be avoided when possible; if required, agents with minimal hepatic metabolism are preferred. Ammonia reduction is achieved with nonabsorbable disaccharides such as lactulose, administered orally, via nasogastric tube, or as retention enemas in severe cases. Intestinal flora reduction may include rifaximin, neomycin, metronidazole, or vancomycin, often in combination with lactulose. Rifaximin is preferred for lactulose-resistant HE due to its efficacy and favorable safety profile. Cerebral edema should be treated promptly if present. Zinc deficiency should be corrected, and short-term protein restriction may be considered. Flumazenil may provide transient improvement in select patients but should be avoided in chronic benzodiazepine or alcohol users. Liver transplantation is the definitive therapy for severe or recurrent HE. Additional therapies under investigation include L-carnitine, albumin dialysis, N-acetylcysteine, probiotics, branched-chain amino acids, and manganese chelation.
Medications
Therapy may include intravenous dextrose for hypoglycemia, lactulose titrated to achieve two to three soft stools daily, rifaximin 550 mg twice daily, neomycin or metronidazole when indicated, naloxone for suspected opioid effect, thiamine supplementation, zinc acetate or sulfate, and mannitol for cerebral edema.
Follow-Up And Disposition
Patients with grade II to IV HE, type A HE of any grade, type B or C HE grade II or higher, associated complications such as sepsis or gastrointestinal bleeding, or diagnostic uncertainty require admission, often to the intensive care unit with gastroenterology consultation. Discharge may be considered for patients with known chronic HE presenting with grade 0 or I symptoms, a reversible cause, and reliable supervision. Discharged patients should receive lactulose therapy and dietary guidance.
Follow-Up Recommendations
Patients should realize the importance of dietary counseling, medication adherence, and alcohol cessation when appropriate. Referral to gastroenterology is recommended for recurrent episodes, and patients with type A HE should be evaluated for liver transplantation.
Clinical Insights And Common Errors
Rifaximin is effective for lactulose-resistant hepatic encephalopathy. Hypoglycemia is common and easily overlooked. Sedatives and narcotics can worsen encephalopathy and should be avoided whenever possible or replaced with agents not metabolized by the liver.
0 Comments
